+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Phase I trial of recombinant granulocyte-macrophage colony-stimulating factor in patients with lung cancer: clinical and immunologic effects



Phase I trial of recombinant granulocyte-macrophage colony-stimulating factor in patients with lung cancer: clinical and immunologic effects



Journal of ImmunoTherapy with Emphasis on Tumor Immunology 13(4): 267-274



Recombinant granulocyte-macrophage colony-stimulating factor (rhuGM-CSF) may enhance the functional activity of monocytes and macrophages in vitro and in vivo and thereby have antitumor activity. A phase I trial using rhuGM-CSF was performed; the trial included 17 patients with unresectable and/or metastatic lung cancer. rhuGM-CSF was administered as a continuous infusion for 14 days at four dose levels: 60 micrograms/m2, 125 micrograms/m2, 250 micrograms/m2, and 500 micrograms/m2. Dose-limiting toxicity was pulmonary and occurred at 500 micrograms/m2, with the maximal tolerated dose (MTD) identified as 250 micrograms/m2. The hematologic effects of rhuGM-CSF included leukocytosis with significant correlations between dose level and the numbers of neutrophils, monocytes, eosinophils, and lymphocytes. Bronchoalveolar lavage was performed for 14 patients, and no effect on alveolar macrophage numbers was detected. Tumor biopsies were obtained in two patients, and no changes in macrophage infiltrates were detected with use of immunohistochemical studies. Serum levels of GM-CSF reached a steady state during week one and decreased or were undetectable during week two. No evidence of tumor regression was seen. rhuGM-CSF when administered as a continuous infusion was well tolerated and appears to modulate monocyte numbers and function in vivo.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 009183259

Download citation: RISBibTeXText

PMID: 8334111

DOI: 10.1097/00002371-199305000-00006


Related references

Comparison of neutrophil and monocyte function by microbicidal cell-kill assay in patients with cancer receiving granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, or no cytokine after cytotoxic chemotherapy: a phase II trial. American Journal of Clinical Oncology 21(3): 308-312, 1998

Randomized clinical trial of the immune stimulating effects of low-dose, perioperative recombinant granulocyte-macrophage colony-stimulating factor treatment in patients operated for primary colorectal carcinoma. Immunobiology 203(1-2): 552, 2000

Phase I trial of recombinant human granulocyte-macrophage colony-stimulating factor derived from yeast in patients with breast cancer receiving cyclophosphamide, doxorubicin, and fluorouracil. Journal of Clinical Oncology 11(12): 2411-2416, 1993

Growth characteristics of marrow hematopoietic progenitor/precursor cells from patients on a phase I clinical trial with purified recombinant human granulocyte-macrophage colony-stimulating factor. Experimental Hematology 16(7): 594-602, 1988

Recombinant human granulocyte macrophage colony stimulating factor gm csf a phase i trial in neutropenic aids patients. Morisset, R A (Ed ) Ve Conference Internationale Sur Le Sida: Le Defi Scientifique Et Social; V International Conference on Aids: The Scientific And Social Challenge; Montreal, Quebec, Canada, June 4-9, 1262p International Development Research Centre: Ottawa, Ontario, Canada Illus Paper 403, 1989

Recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy: a phase Ib trial. Journal of the National Cancer Institute 82(8): 697-703, 1990

Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes--a phase I/II trial. Blood 73(1): 31-37, 1989

Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes--a phase-I/II trial. Onkologie 11(1): 53-55, 1988

A phase i trial with recombinant human granulocyte macrophage colony stimulating factor derived from yeast rhugm csf in patients with breast cancer receiving caf chemotherapy in adjuvant and metastatic disease. Breast Cancer Research & Treatment 19(2): 168, 1991

Phase I trial of recombinant human granulocyte-macrophage colony stimulating factor. Results in patients with advanced tumors. Bulletin du Cancer 80(5): 418-430, 1993

A randomized trial of recombinant human granulocyte-macrophage colony stimulating factor for patients with acute lung injury. Critical Care Medicine 40(1): 90-97, 2012

Nursing care of AIDS patients participating in a Phase I/II trial of recombinant human granulocyte-macrophage colony stimulating factor. Oncology Nursing Forum 15(4): 463-469, 1988

Phase Ia/Ib trial of recombinant granulocyte macrophage colony stimulating factor and monoclonal antibody ch1418 in patients with metastatic melanoma. Journal of Interferon & Cytokine Research 17(Suppl. 2): S103, 1997

Phase I trial of granulocyte-macrophage colony-stimulating factor with high-dose cisplatin and etoposide for treatment of small-cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group. Journal of the National Cancer Institute 84(1): 59-60, 1992